Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

New Effects of Prebiotics, Probiotics, and Symbiotics.

Current clinical pharmacology·2020
Same journal

Prenatal Administration of Betamethasone and Neonatal Respiratory Distress Syndrome in Multifetal Pregnancies: A Randomized Controlled Trial.

Current clinical pharmacology·2020
Same journal

Repurposing Available Anti-inflammatory and Immunomodulating Agents for Cardiovascular Risk Management: A Call for Submissions to Current Clinical Pharmacology.

Current clinical pharmacology·2020
Same journal

Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?

Current clinical pharmacology·2020
Same journal

Effects of Probiotics on Diabetic Nephropathy: A Systematic Review.

Current clinical pharmacology·2020
Same journal

Therapeutic Effects of Prebiotics on Constipation: A Schematic Review.

Current clinical pharmacology·2020
See all related articles

Related Experiment Video

Updated: May 6, 2026

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.2K

CD26: a multi-purpose pharmacological target.

Formica Vincenzo, Tesauro Manfredi, Cardillo Carmine

  • 1Medical Oncology Unit, Internal Medicine Department, University Hospital 'Tor Vergata' , Viale Oxford, 81, 00133 Rome, Italy. v.formica1@gmail.com.

Current Clinical Pharmacology
|November 14, 2013
PubMed
Summary
This summary is machine-generated.

This review explores CD26 (dipeptidyl peptidase-4) as a pharmacological target. Inhibiting CD26 can enhance glucagon-like peptide-1 (GLP-1) for diabetes treatment and impact cardiovascular disease and cancer.

More Related Videos

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

503
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.4K

Related Experiment Videos

Last Updated: May 6, 2026

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.2K
Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling
07:51

Single-Molecule Localization Microscopy of Membrane Proteins using Single-Antibody Labeling

Published on: March 20, 2026

503
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
06:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

13.4K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • CD26 is a transmembrane glycoprotein with peptidase activity.
  • It regulates biological processes and catabolizes circulating proteins.
  • CD26 is implicated in diabetes, cardiovascular disease, and cancer.

Purpose of the Study:

  • To review pharmacological interventions targeting CD26.
  • To summarize CD26's role in diabetes, cardiovascular health, cancer, and immune modulation.

Main Methods:

  • Literature review of studies on CD26-based pharmacological interventions.
  • Analysis of CD26's role in GLP-1 bioavailability, cardiovascular physiology/pathology, cancer prognosis, and immune responses.

Main Results:

  • CD26 inhibitors can increase GLP-1 levels, improving glucose control in diabetes.
  • CD26 plays a role in cardiovascular system function and pathology.
  • CD26 expression on cancer cells has adverse prognostic value.
  • CD26 downregulation on lymphocytes is linked to TGF-beta immunomodulation.

Conclusions:

  • CD26 is a versatile pharmacological target with potential applications in metabolic, cardiovascular, and oncological diseases.
  • Modulating CD26 activity offers therapeutic strategies for various pathological conditions.
  • Further research into CD26-based interventions is warranted for clinical translation.